Longeveron Inc. (LGVN) Stock Profile — Insider Trades & Financials

Revenue$365.0K

Net Income-$5.4M

EPS$-0.22

Gross Margin70.4%

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Stephen Willard

CEO & Executive Director

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimerâs disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Founded: 2014
Employees: 25
Headquarters: Miami, Florida, United States

⚡

Core Efficiency

ROE?

-95.93%

ROA?

-53.06%

D/E Ratio?

0.81

Op. Margin?

-1479.18%

📊

Profitability Ratios

Net Margin?

-1491.51%

Loading company sections...

Longeveron Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness